Introduction: Serotonin-modulating medications are commonly prescribed for mental health issues. Currently, there is limited consensus on weight gain and dysglycaemia development among children using these medications. The objective of this study is to review and synthesise all the available evidence on serotonin-modulating medications and their effects on body mass index (BMI), weight and glycaemic control.
Methods And Analysis: We will conduct a systematic review of all randomised controlled trials evaluating the use of serotonin-modulating medications in the treatment of children 2-17 years with mental health conditions. The outcome measures are BMI, weight and dysglycaemia. We will perform literature searches through Ovid Medline, Ovid Embase, PsycINFO and grey literature resources. Two reviewers from the team will independently screen titles and abstracts, assess the eligibility of full-text trials, extract information from eligible trials and assess the risk of bias and quality of the evidence. Results of this review will be summarised narratively and quantitatively as appropriate. We will perform a multiple treatment comparison using network meta-analysis to estimate the pooled direct, indirect and network estimate for all serotonin-modulating medications on outcomes if adequate data are available.
Ethics And Dissemination: Serotonin-modulating medications are widely prescribed for children with mental health diseases and are also used off-label. This network meta-analysis will be the first to assess serotonin modulating antidepressants and their effects on weight and glycaemic control. We anticipate that our results will help physicians and patients make more informed choices while considering the side effect profile. We will disseminate the results of the systematic review and network meta-analysis through peer-reviewed journals.
Prospero Registration Number: CRD42015024367.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4800145 | PMC |
| http://dx.doi.org/10.1136/bmjopen-2015-009998 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Serotonin Availability Shapes the Effects of Phenelzine on Inflammatory Response and Gene Expression in Macrophages.
Cureus
October 2024
Medical Immunology, Cancer Research Center, Golestan University of Medical Sciences, Gorgan, IRN.
Background Serotonin (5-HT) is a neurotransmitter with extensive physiological influence in the central nervous system (CNS) and various behavioral and biological functions, including immune regulation through 5-HT receptors (5-HTRs) expressed by immune cells. A variety of serotonin-modulating drugs have been developed to treat neurological disorders. Phenelzine, a drug indicated for the management of treatment-resistant depression, is a potent, non-selective inhibitor of monoamine oxidase (MAO), the enzyme that metabolizes serotonin to 5-hydroxyindole acetic acid (5-HIAA).
View Article and Find Full Text PDFEfficacy of a Serotonin-Norepinephrine Reuptake Inhibitor as a Treatment for Meniere Disease: A Randomized Clinical Trial.
JAMA Otolaryngol Head Neck Surg
November 2024
Department of Otolaryngology-Head and Neck Surgery, Medical University of South Carolina, Charleston.
Article Synopsis
- Meniere disease, responsible for 15% of vestibular disorders, lacks an effective treatment to manage vertigo episodes, prompting further research into potential therapies.
- The study aimed to evaluate the effectiveness of the medication venlafaxine against a placebo in alleviating symptoms of Meniere disease in a controlled clinical trial over 22 weeks.
- A total of 40 patients participated, receiving either venlafaxine or placebo, with key measures focusing on the frequency of vertigo episodes and patients' overall health-related quality of life.
Influence of variants in serotonin modulating genes on the risk, aggressiveness, and prognosis of oropharynx cancer.
Head Neck
July 2023
Laboratory of Cancer Genetics, School of Medical Sciences, University of Campinas, Campinas, Brazil.
Article Synopsis
- Serotonin (5-HT) is linked to tumor growth and psychiatric disorders, and certain single-nucleotide variations (SNVs) in genes related to serotonin synthesis and receptors may affect 5-HT levels in oropharynx carcinoma (OPC).
- Analysis of DNA from 251 OPC patients and 254 controls revealed that the TPH1 TT variant was more common in patients, while HTR1D variants were associated with more aggressive tumors and shorter survival.
- The findings indicate that genetic variations in serotonin-related genes could potentially impact the development and progression of OPC, highlighting the need for further research in this area.
Serotonin depletion amplifies distinct human social emotions as a function of individual differences in personality.
Transl Psychiatry
February 2021
Department of Psychology, University of Cambridge, Cambridge, UK.
Serotonin is involved in a wide range of mental capacities essential for navigating the social world, including emotion and impulse control. Much recent work on serotonin and social functioning has focused on decision-making. Here we investigated the influence of serotonin on human emotional reactions to social conflict.
View Article and Find Full Text PDFIntracranial Hemorrhage from Meningioma: 2 Novel Risk Factors.
World Neurosurg
March 2020
Department of Neurosurgery, Brigham and Women's Hospital, Harvard Medical School, Boston, Massachusetts, USA. Electronic address:
Background: Meningiomas are the most common benign intracranial tumor. Although meningiomas are slow growing and potentially highly vascularized, hemorrhage of these tumors is rare. We propose 2 novel modifiable risk factors that may provoke intratumoral hemorrhage of a World Health Organization grade I meningioma.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!